minimal Common Oncology Data Elements (mCODE) Implementation Guide
4.0.0 - STU4 United States of America flag

minimal Common Oncology Data Elements (mCODE) Implementation Guide, published by HL7 International / Clinical Interoperability Council. This guide is not an authorized publication; it is the continuous build for version 4.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/fhir-mCODE-ig/ and changes regularly. See the Directory of published versions

: cancer-related-medication-admin-doxorubicin-jenny-m - XML Representation

Raw xml | Download


<MedicationAdministration xmlns="http://hl7.org/fhir">
  <id value="cancer-related-medication-admin-doxorubicin-jenny-m"/>
  <meta>
    <profile
             value="http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-cancer-related-medication-administration"/>
  </meta>
  <text>
    <status value="extensions"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: MedicationAdministration cancer-related-medication-admin-doxorubicin-jenny-m</b></p><a name="cancer-related-medication-admin-doxorubicin-jenny-m"> </a><a name="hccancer-related-medication-admin-doxorubicin-jenny-m"> </a><a name="cancer-related-medication-admin-doxorubicin-jenny-m-en-US"> </a><p><b>Normalization Basis Extension</b>: <span title="Codes:{http://snomed.info/sct 363804004}">Body weight characteristic (observable entity)</span></p><p><b>status</b>: Completed</p><p><b>category</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/medicationrequest-category outpatient}">Outpatient</span></p><p><b>medication</b>: <span title="Codes:{http://www.nlm.nih.gov/research/umls/rxnorm 1790099}">10 ML doxorubicin hydrochloride 2 MG/ML Injection</span></p><p><b>subject</b>: <a href="Patient-cancer-patient-jenny-m.html">Jenny M  Female, DoB: 1965-01-01 ( Medical Record Number: MRN1234 (use: usual, ))</a></p><p><b>effective</b>: 2018-04-22</p><h3>Performers</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Actor</b></td></tr><tr><td style="display: none">*</td><td><a href="Practitioner-us-core-practitioner-nancy-oncology-nurse.html">Practitioner Nancy Nurse </a></td></tr></table><p><b>reasonReference</b>: <a href="Condition-primary-cancer-condition-jenny-m.html">Condition Primary malignant neoplasm of female left breast (disorder)</a></p><p><b>request</b>: <a href="MedicationRequest-cancer-related-medication-request-doxorubicin-jenny-m.html">MedicationRequest: extension = Curative - procedure intent (qualifier value); status = active; intent = order; category = Outpatient; medication[x] = DOXOrubicin; authoredOn = 2018-04-12</a></p><p><b>note</b>: doxorubicin (60 mg/m² IV), 105.96 mg in 50 ml 0.9% normal saline administered by continuous infusion. Patient tolerated infusion without side effects. (By Practitioner/us-core-practitioner-nancy-oncology-nurse @2018-04-22)</p><h3>Dosages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Route</b></td><td><b>Dose</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://snomed.info/sct 47625008}">Intravenous route (qualifier value)</span></td><td>105.96 mg<span style="background: LightGoldenRodYellow"> (Details: UCUM  codemg = 'mg')</span></td></tr></table></div>
  </text>
  <extension
             url="http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-normalization-basis">
    <valueCodeableConcept>
      <coding>
        <system value="http://snomed.info/sct"/>
        <code value="363804004"/>
        <display value="Body weight characteristic (observable entity)"/>
      </coding>
    </valueCodeableConcept>
  </extension>
  <status value="completed"/>
  <category>
    <coding>
      <system
              value="http://terminology.hl7.org/CodeSystem/medicationrequest-category"/>
      <code value="outpatient"/>
    </coding>
  </category>
  <medicationCodeableConcept>
    <coding>
      <system value="http://www.nlm.nih.gov/research/umls/rxnorm"/>
      <code value="1790099"/>
      <display value="10 ML doxorubicin hydrochloride 2 MG/ML Injection"/>
    </coding>
  </medicationCodeableConcept>
  <subject>🔗 
    <reference value="Patient/cancer-patient-jenny-m"/>
  </subject>
  <effectiveDateTime value="2018-04-22"/>
  <performer>
    <actor>🔗 
      <reference
                 value="Practitioner/us-core-practitioner-nancy-oncology-nurse"/>
    </actor>
  </performer>
  <reasonReference>🔗 
    <reference value="Condition/primary-cancer-condition-jenny-m"/>
  </reasonReference>
  <request>🔗 
    <reference
               value="MedicationRequest/cancer-related-medication-request-doxorubicin-jenny-m"/>
  </request>
  <note>
    <authorReference>🔗 
      <reference
                 value="Practitioner/us-core-practitioner-nancy-oncology-nurse"/>
    </authorReference>
    <time value="2018-04-22"/>
    <text
          value="doxorubicin (60 mg/m² IV), 105.96 mg in 50 ml 0.9% normal saline administered by continuous infusion. Patient tolerated infusion without side effects."/>
  </note>
  <dosage>
    <route>
      <coding>
        <system value="http://snomed.info/sct"/>
        <code value="47625008"/>
        <display value="Intravenous route (qualifier value)"/>
      </coding>
    </route>
    <dose>
      <value value="105.96"/>
      <unit value="mg"/>
      <system value="http://unitsofmeasure.org"/>
      <code value="mg"/>
    </dose>
  </dosage>
</MedicationAdministration>